- Home
- NBIX vs PEN Comparison
NBIX vs PEN Comparison
Compare NBIX & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | PEN |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 12.2B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBIX | PEN |
|---|---|---|
| Price | $135.92 | $315.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 15 |
| Target Price | $177.29 | ★ $332.40 |
| AVG Volume (30 Days) | ★ 1.0M | 441.4K |
| Earning Date | 02-05-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.44 | ★ 367.34 |
| EPS | ★ 4.19 | 4.14 |
| Revenue | ★ $2,682,700,000.00 | $1,333,798,000.00 |
| Revenue This Year | $23.68 | $16.77 |
| Revenue Next Year | $18.47 | $14.12 |
| P/E Ratio | ★ $33.55 | $76.40 |
| Revenue Growth | ★ 19.61 | 14.61 |
| 52 Week Low | $84.23 | $221.26 |
| 52 Week High | $160.18 | $321.38 |
Technical Indicators
Market Signals| Indicator | NBIX | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 59.78 |
| Support Level | $134.03 | $305.30 |
| Resistance Level | $142.16 | $320.42 |
| Average True Range (ATR) | 3.13 | 7.82 |
| MACD | -1.09 | -1.48 |
| Stochastic Oscillator | 11.91 | 64.77 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.